CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
EURE-CART focuses on advancing CAR T-cell immunotherapy for cancer treatment in Europe. The project aims to initiate clinical trials for previously untreatable tumors, fostering collaboration among academia, industry, and regulatory bodies to enhance patient outcomes.
Cancer is rapidly becoming the most frequent cause of death in EU.
Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases.
Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing secondary chronic diseases.
This approach is already at an advanced stage of development in the US,…
AGC BIOLOGICS SPA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Milano
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Italy, Milano
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Germany, Wurzburg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
OSPEDALE PEDIATRICO BAMBINO GESU
Italy, Roma
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
